What medications are suggested for the management of NSTEMI, and what is the recommended time scale for their administration?

Zenodo (CERN European Organization for Nuclear Research) 2026 Open access

Read full text
Authors: Tripdatabase
DOI: 10.5281/zenodo.18785413
Cited by: 0

Abstract

NSTEMI management involves prompt administration of antiplatelet and anticoagulant therapies to minimize cardiac damage, with ongoing dual antiplatelet therapy often extending up to 12 months.

Fields of Study & Subjects

Antiplatelet Therapy and Cardiovascular Diseases Acute Myocardial Infarction Research Coronary Interventions and Diagnostics

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
9 February 2026
Language
EN